Drug Profile
Research programme: cancer therapeutics - L.E.A.F. Pharmaceuticals
Alternative Names: LEAF 1701; LEAF 1702; LEAF 1703; LEAF-1402; LEAF-1402-1602; LEAF-1403; LEAF-1801; LEAF-1802; LEAF-1803; LEAF-5816Latest Information Update: 28 Jun 2021
Price :
$50
*
At a glance
- Originator L.E.A.F. Pharmaceuticals
- Class Antineoplastics
- Mechanism of Action One-carbon group transferase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes - Cancer
Highest Development Phases
- No development reported Solid tumours
Most Recent Events
- 28 Jun 2021 No recent reports of development identified for preclinical development in Solid-tumours in USA
- 18 Jun 2019 Cancer Therapeutics research programme is still in preclinical development USA (L.E.A.F Pharmaceticals pipeline, June 2019)
- 03 Jun 2019 Pharmacodynamics data from a preclinical studies in Cancer presented at the 55th Annual Meeting of the American Society of Clinical Oncology (ASCO-2019)